Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972517 | 0.85 | LMNA (0.60) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL20176876 | 0.85 | LMNA (0.60) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL30535283 | 0.83 | LMNA (0.82) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL676142 | 0.83 | LMNA (0.82) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| Potassium SCHEMBL6776357 | 0.81 | LMNA (0.78) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL754535 | 0.79 | LTA4H (0.55) | LMNATDP1CYP11B1CYP11B2LTA4H | |
| SCHEMBL16114401 | 0.79 | LMNA (0.75) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL169035 | 0.78 | LMNA (0.62) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL20176875 | 0.78 | LTA4H (0.39) | LMNATDP1CYP11B1CYP11B2LTA4H | |
| SCHEMBL14831395 | 0.78 | LMNA (0.51) | LMNATDP1CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | LMNA 946/4885TDP1 1826/4885CYP11B1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.